Analysis Tools
mortality/aging
|
• 71% of mice treated with pIpC, G-CSF, and ENU exhibit thymic tumors, splenomegaly, and/or death 10 months after treatment
|
hematopoietic system
| N |
• mice exhibit normal peripheral blood cell counts up to 1.5 years following induction with pIpC at 6 weeks
|
|
• at 1.5 years of age, 29% of enlarged spleens from mice induced with pIpC at 6 weeks exhibit myeloproliferative disorder compared to 7% of wild-type enlarged spleens
|
|
• after 4 weeks of pIpC induction, the frequency of hematopoietic stem cells in the bone marrow is decreased compared to in wild-type mice
• however, at 1.5 years of age pIpC-induced mice exhibit a normal of hematopoeitic stem cells
|
|
• at 3 months, spleen structure in mice induced with pIpC at 6 weeks is moderately effaced unlike in wild-type mice
|
|
• at 3 months, one mouse induced with pIpC at 6 weeks exhibited an enlarged spleen
• at 1.5 years of age, 47% of mice induced with pIpC at 6 weeks exhibit enlarged spleen compared to 20% in Tg(Mx1-cre)1Cgn mice
• 71% of mice treated with pIpC, G-CSF, and ENU exhibit thymic tumors, splenomegaly, and/or death 10 months after treatment
|
|
• at 1.5 years of age in mice induced with pIpC at 6 weeks
|
neoplasm
|
• mice treated with pIpC, G-CSF, and ENU exhibit myeloid and lymphoid neoplasias
|
|
• 71% of mice treated with pIpC, G-CSF, and ENU exhibit thymic tumors, splenomegaly, and/or death 10 months after treatment
|
|
• in one mouse induced with pIpC at 6 weeks
|
|
• in one 9 month old in mouse induced with pIpC at 6 weeks
|
immune system
|
• at 1.5 years of age, 29% of enlarged spleens from mice induced with pIpC at 6 weeks exhibit myeloproliferative disorder compared to 7% of wild-type enlarged spleens
|
|
• at 3 months, spleen structure in mice induced with pIpC at 6 weeks is moderately effaced unlike in wild-type mice
|
|
• at 3 months, one mouse induced with pIpC at 6 weeks exhibited an enlarged spleen
• at 1.5 years of age, 47% of mice induced with pIpC at 6 weeks exhibit enlarged spleen compared to 20% in Tg(Mx1-cre)1Cgn mice
• 71% of mice treated with pIpC, G-CSF, and ENU exhibit thymic tumors, splenomegaly, and/or death 10 months after treatment
|
|
• at 1.5 years of age in mice induced with pIpC at 6 weeks
|
homeostasis/metabolism
|
• 71% of mice treated with pIpC, G-CSF, and ENU exhibit thymic tumors, splenomegaly, and/or death 10 months after treatment
|
endocrine/exocrine glands
|
• 71% of mice treated with pIpC, G-CSF, and ENU exhibit thymic tumors, splenomegaly, and/or death 10 months after treatment
|
growth/size/body
|
• at 3 months, one mouse induced with pIpC at 6 weeks exhibited an enlarged spleen
• at 1.5 years of age, 47% of mice induced with pIpC at 6 weeks exhibit enlarged spleen compared to 20% in Tg(Mx1-cre)1Cgn mice
• 71% of mice treated with pIpC, G-CSF, and ENU exhibit thymic tumors, splenomegaly, and/or death 10 months after treatment
|
liver/biliary system
|
• in one mouse induced with pIpC at 6 weeks
|
|
• in one 9 month old in mouse induced with pIpC at 6 weeks
|
